We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Aduro Initiates Dosing in Phase I Melanoma Study on ADU-S100
Read MoreHide Full Article
Aduro BioTech, Inc. announced that it has dosed the first patient in a phase I study, evaluating its lead STING Activator candidate, ADU-S100, in combination with Bristol-Myers’ (BMY - Free Report) Yervoy (ipilimumab) for the treatment of relapsed/refractory melanoma.
Earlier, ADU-S100 was being evaluated as a single agent. However, the protocol was amended later to include the evaluation of ADU-S100 in combination with Yervoy on a homogeneous patient population.
Shares of Aduro were up almost 5.4% following the news on Monday. However, the stock has plunged 42.9% in the past year, wider than the industry’s decrease of 17.6%.
This study is part of Aduro’s ongoing research and development collaboration with Novartis (NVS - Free Report) for ADU-S100. The same will enroll patients afflicted with advanced melanoma, who have relapsed after or are refractory to other anti-PD-1 antibodies, such as Bristol-Myers’ Opdivo (nivolumab) or Merck’s (MRK - Free Report) Keytruda (pembrolizumab).
ADU-S100 is also being evaluated in a phase I program as a monotherapy on patients with cutaneously accessible metastatic solid tumors or lymphomas. Top-line data from the same is expected soon.
Aduro is also conducting a phase Ib analysis to assess ADU-S100 in combination with Novartis’ PD-1 checkpoint inhibitor, PDR001, for treating solid tumors and lymphomas.
Notably, Aduro has been pursuing acquisitions and agreements to help sponsor its pipeline development.
We would like to remind investors that last December, Aduro entered into an exclusive collaboration and license agreement with pharma giant Eli Lilly to develop novel immunotherapies for autoimmune and other inflammatory diseases by leveraging its cGAS-STING inhibitor platform.
Moreover, the company has granted Janssen Biotech, a subsidiary of Johnson & Johnson, an exclusive, worldwide license to develop its cancer candidates, namely ADU-214 and ADU-741.
It's hard to believe, even for us at Zacks. But from 2000-2018, while the market gained +4.8% per year, our top stock-picking strategy averaged +54.3% per year.
How has that screen done lately? From 2017-2018, it sextupled the market's +15.8% gain with a soaring +98.3% return.
Image: Bigstock
Aduro Initiates Dosing in Phase I Melanoma Study on ADU-S100
Aduro BioTech, Inc. announced that it has dosed the first patient in a phase I study, evaluating its lead STING Activator candidate, ADU-S100, in combination with Bristol-Myers’ (BMY - Free Report) Yervoy (ipilimumab) for the treatment of relapsed/refractory melanoma.
Earlier, ADU-S100 was being evaluated as a single agent. However, the protocol was amended later to include the evaluation of ADU-S100 in combination with Yervoy on a homogeneous patient population.
Shares of Aduro were up almost 5.4% following the news on Monday. However, the stock has plunged 42.9% in the past year, wider than the industry’s decrease of 17.6%.
This study is part of Aduro’s ongoing research and development collaboration with Novartis (NVS - Free Report) for ADU-S100. The same will enroll patients afflicted with advanced melanoma, who have relapsed after or are refractory to other anti-PD-1 antibodies, such as Bristol-Myers’ Opdivo (nivolumab) or Merck’s (MRK - Free Report) Keytruda (pembrolizumab).
ADU-S100 is also being evaluated in a phase I program as a monotherapy on patients with cutaneously accessible metastatic solid tumors or lymphomas. Top-line data from the same is expected soon.
Aduro is also conducting a phase Ib analysis to assess ADU-S100 in combination with Novartis’ PD-1 checkpoint inhibitor, PDR001, for treating solid tumors and lymphomas.
Notably, Aduro has been pursuing acquisitions and agreements to help sponsor its pipeline development.
We would like to remind investors that last December, Aduro entered into an exclusive collaboration and license agreement with pharma giant Eli Lilly to develop novel immunotherapies for autoimmune and other inflammatory diseases by leveraging its cGAS-STING inhibitor platform.
Moreover, the company has granted Janssen Biotech, a subsidiary of Johnson & Johnson, an exclusive, worldwide license to develop its cancer candidates, namely ADU-214 and ADU-741.
Zacks Rank
Aduro currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks' Best Stock-Picking Strategy
It's hard to believe, even for us at Zacks. But from 2000-2018, while the market gained +4.8% per year, our top stock-picking strategy averaged +54.3% per year.
How has that screen done lately? From 2017-2018, it sextupled the market's +15.8% gain with a soaring +98.3% return.
Free – See the Stocks It Turned Up for Today >>